A Phase 1, Open-Label Study, to Evaluate the Safety and Tolerability of multiple inhalation of SM04646 Inhalation Solution in Subjects with Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs SM 04646 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Samumed
- 28 Jun 2018 Planned number of patients changed from 12 to 10.
- 28 Jun 2018 Planned End Date changed from 31 Jan 2018 to 30 Dec 2018.
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.